Neratinib + capecitabine vs. lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial - Saura, C; Oliveira, M; Feng, Y H (JCO ASCO Ann Meeting, 2019)